U.S., March 21 -- ClinicalTrials.gov registry received information related to the study (NCT07486726) titled 'Aclarubicin Plus With Azacitidine and Venetoclax in the Treatment of Acute Myeloid Leukemia' on March 12.
Brief Summary: Acute myeloid leukemia Acute myeloid leukemia (AML) is a clonal hematopoietic cancer that disrupts normal hematopoiesis, ultimately leading to bone marrow failure and death. The annual incidence rate of AML is 4.1 per 100000 people in the US and is higher in patients older than 65 years. There has been a steady improvement in survival over the decades, more noticeably so in younger patients and in the last decade. Azacitidine and Venetoclax is now the standard treatment of newly diagnosed AML ineligible for inten...